PE20110345A1 - Anticuerpos contra la il17 humana - Google Patents
Anticuerpos contra la il17 humanaInfo
- Publication number
- PE20110345A1 PE20110345A1 PE2011000642A PE2011000642A PE20110345A1 PE 20110345 A1 PE20110345 A1 PE 20110345A1 PE 2011000642 A PE2011000642 A PE 2011000642A PE 2011000642 A PE2011000642 A PE 2011000642A PE 20110345 A1 PE20110345 A1 PE 20110345A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- region
- antibody
- antibodies against
- against human
- Prior art date
Links
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 title 1
- 102100033461 Interleukin-17A Human genes 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
Abstract
REFERIDA A UN ANTICUERPO QUE SE UNE A LA IL-17 HUMANA QUE COMPRENDE: a) UN DOMINIO VARIABLE DE CADENA LARGA QUE CONTIENE UNA REGION CDR3 DE LA SEQ ID NO: 1, UNA REGION CDR2 DE LA SEQ ID NO: 2 O 9 Y UNA REGION CDR1 DE LA SEQ ID NO: 3 Y b) UN DOMINIO VARIABLE DE CADENA CORTA QUE CONTIENE UNA REGION CDR3 DE LA SEQ ID NO:4, UNA REGION CDR2 DE LA SEQ ID NO:5 Y UNA REGION CDR1 DE LA SEQ ID NO:6, DONDE EL ANTICUERPO ES UN ANTICUERPO QUIMERICO, HUMANIZADO O ES UNA VARIANTE DEL ANTICUERPO 3C1 DESPROVISTO DEL EPITOPE DE CELULA T. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA, UN VECTOR, UN ACIDO NUCLEICO Y UNA LINEA CELULAR DE HIBRIDOMAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08017155 | 2008-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110345A1 true PE20110345A1 (es) | 2011-06-13 |
Family
ID=40352697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000642A PE20110345A1 (es) | 2008-09-29 | 2009-09-21 | Anticuerpos contra la il17 humana |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8003099B2 (es) |
| EP (1) | EP2331575B1 (es) |
| JP (2) | JP5581323B2 (es) |
| KR (1) | KR101318549B1 (es) |
| CN (2) | CN102617735B (es) |
| AR (1) | AR073692A1 (es) |
| AU (1) | AU2009296299A1 (es) |
| BR (1) | BRPI0919531A2 (es) |
| CA (1) | CA2737636A1 (es) |
| CL (1) | CL2011000672A1 (es) |
| CO (1) | CO6351795A2 (es) |
| CR (1) | CR20110161A (es) |
| EC (1) | ECSP11010911A (es) |
| ES (1) | ES2493042T3 (es) |
| IL (1) | IL211684A0 (es) |
| MA (1) | MA32725B1 (es) |
| MX (1) | MX2011003184A (es) |
| MY (1) | MY153893A (es) |
| NZ (1) | NZ591484A (es) |
| PE (1) | PE20110345A1 (es) |
| RU (1) | RU2539029C2 (es) |
| TW (1) | TWI393570B (es) |
| UA (1) | UA103499C2 (es) |
| WO (1) | WO2010034443A1 (es) |
| ZA (1) | ZA201102004B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641822B1 (en) | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| WO2010034443A1 (en) * | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| AU2010313304B2 (en) | 2009-10-30 | 2015-08-20 | Janssen Biotech, Inc. | IL-17A antagonists |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| NZ607615A (en) * | 2010-08-05 | 2015-03-27 | Anaptysbio Inc | Antibodies directed against il-17 |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| HRP20251174T1 (hr) | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| WO2012076442A1 (en) | 2010-12-07 | 2012-06-14 | F. Hoffmann-La Roche Ag | Adapter for the non-invasive cultivation of cells and uses thereof |
| EP2649176B1 (en) | 2010-12-07 | 2018-01-17 | F. Hoffmann-La Roche AG | Feed mixing device and its use |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| CN102188707B (zh) * | 2011-02-25 | 2015-08-05 | 中国医学科学院基础医学研究所 | Il-17抑制剂在制备治疗流感的药物中的用途 |
| ES2865449T3 (es) | 2011-03-16 | 2021-10-15 | Hoffmann La Roche | Cromatografía de intercambio iónico con selectividad mejorada para la separación de monómeros, agregados y fragmentos polipeptídicos por modulación de la fase móvil |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| EP2783014A1 (en) | 2011-11-21 | 2014-10-01 | Novartis AG | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
| PE20142422A1 (es) | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos |
| KR20150010709A (ko) | 2012-04-20 | 2015-01-28 | 노파르티스 아게 | Il-17 길항제를 사용하는 강직성 척추염의 치료 방법 |
| EP3590537A1 (en) | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| AP2015008584A0 (en) * | 2013-02-08 | 2015-07-31 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| US10434172B2 (en) | 2013-08-15 | 2019-10-08 | Novartis Ag | Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists |
| KR102278487B1 (ko) * | 2013-11-18 | 2021-07-19 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Ｉｌ-17ａ 접합체 및 이의 용도 |
| KR20160113268A (ko) * | 2014-01-28 | 2016-09-28 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 이기능 융합단백질,이의 제조방법 및 용도 |
| DK3122775T3 (da) | 2014-03-26 | 2020-02-03 | Univ Wuerzburg J Maximilians | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
| CA2960754A1 (en) | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3250927B1 (en) | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN108251431B (zh) * | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
| BR112018006218A2 (pt) | 2015-10-02 | 2018-10-09 | Univ Wuerzburg J Maximilians | iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15 |
| AU2016333538B2 (en) | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| WO2017221174A1 (en) | 2016-06-22 | 2017-12-28 | Novartis Ag | Methods of treating vitiligo using interleukin-17 (il-17) antibodies |
| US20190194311A1 (en) | 2016-07-19 | 2019-06-27 | Novartis Ag | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |
| EA201990673A1 (ru) * | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты |
| SG11201903737PA (en) | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| JP2019505516A (ja) | 2016-11-28 | 2019-02-28 | ノバルティス アーゲー | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |
| WO2018158741A1 (en) | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
| US10676522B2 (en) | 2017-05-05 | 2020-06-09 | Novartis Ag | Methods of selectively treating asthma using IL-17 antagonists |
| CN109206515B (zh) * | 2017-07-06 | 2021-10-12 | 北京伟峰益民科技有限公司 | 一种全人源抗人白介素17a抗体及其应用 |
| CN111344043A (zh) | 2017-11-02 | 2020-06-26 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 |
| KR102048475B1 (ko) * | 2017-11-10 | 2019-11-26 | 주식회사 와이바이오로직스 | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 |
| US20200277369A1 (en) | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
| CN113603776B (zh) * | 2018-02-12 | 2022-10-21 | 原启生物科技(上海)有限责任公司 | Il17抗体及其应用 |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| JP6930778B2 (ja) * | 2018-05-17 | 2021-09-01 | 江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用 |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| CN120025437A (zh) | 2019-01-31 | 2025-05-23 | 努玛治疗有限公司 | 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法 |
| EP4031570A1 (en) | 2019-09-20 | 2022-07-27 | Novartis AG | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| JP7504992B2 (ja) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用 |
| AU2020386669A1 (en) | 2019-11-19 | 2022-06-02 | Novartis Ag | Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists |
| KR20220110512A (ko) | 2019-12-06 | 2022-08-08 | 노파르티스 아게 | 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법 |
| AU2023272370A1 (en) | 2022-05-16 | 2025-01-02 | Albert-Ludwigs-Universität Freiburg | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists |
| CN119546340A (zh) | 2022-05-18 | 2025-02-28 | 诺华股份有限公司 | 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法 |
| CN119074914B (zh) * | 2023-06-05 | 2025-04-25 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的药物制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US5716623A (en) | 1994-12-07 | 1998-02-10 | Immunex Corporation | Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules |
| US6063372A (en) * | 1995-10-27 | 2000-05-16 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Uses of mammalian CTLA-8 and related reagents |
| WO1997015320A1 (en) | 1995-10-27 | 1997-05-01 | Schering Corporation | Novel uses of mammalian ctla-8 and related reagents |
| US6271014B1 (en) | 1998-01-09 | 2001-08-07 | Schering-Plough | Mammalian proteinases; related reagents and methods |
| US6333345B1 (en) | 1999-05-14 | 2001-12-25 | Sepracor, Inc. | Methods of using and compositions comprising N-desmethylzolpidem |
| CN1341660A (zh) * | 2000-09-07 | 2002-03-27 | 上海博德基因开发有限公司 | 一种新的多肽——人白细胞介素受体－配体(il－17b和il－17br)32.56和编码这种多肽的多核苷酸 |
| DK1983000T3 (en) | 2003-11-21 | 2015-12-07 | Ucb Biopharma Sprl | A method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| DK1963368T6 (da) * | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| JP5068270B2 (ja) * | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008002115A1 (fr) | 2006-06-27 | 2008-01-03 | Vladimir Guzenko | Appareil hydraulique à membrane transformant la force de gravitation en couple de torsion destiné à un moteur sans carburant et moteur correspondant |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7846443B2 (en) * | 2006-08-11 | 2010-12-07 | Schering Corporation | Antibodies to IL-17A |
| WO2010034443A1 (en) * | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
-
2009
- 2009-09-21 WO PCT/EP2009/006784 patent/WO2010034443A1/en not_active Ceased
- 2009-09-21 CN CN201210082545.2A patent/CN102617735B/zh not_active Expired - Fee Related
- 2009-09-21 CA CA2737636A patent/CA2737636A1/en not_active Abandoned
- 2009-09-21 UA UAA201105113A patent/UA103499C2/ru unknown
- 2009-09-21 CN CN2009801376495A patent/CN102164959A/zh not_active Withdrawn
- 2009-09-21 NZ NZ591484A patent/NZ591484A/xx not_active IP Right Cessation
- 2009-09-21 MX MX2011003184A patent/MX2011003184A/es active IP Right Grant
- 2009-09-21 MY MYPI2011001382A patent/MY153893A/en unknown
- 2009-09-21 PE PE2011000642A patent/PE20110345A1/es not_active Application Discontinuation
- 2009-09-21 BR BRPI0919531A patent/BRPI0919531A2/pt not_active IP Right Cessation
- 2009-09-21 ES ES09815646.6T patent/ES2493042T3/es active Active
- 2009-09-21 JP JP2011528223A patent/JP5581323B2/ja not_active Expired - Fee Related
- 2009-09-21 RU RU2011116927/10A patent/RU2539029C2/ru not_active IP Right Cessation
- 2009-09-21 AU AU2009296299A patent/AU2009296299A1/en not_active Abandoned
- 2009-09-21 EP EP09815646.6A patent/EP2331575B1/en not_active Not-in-force
- 2009-09-21 KR KR1020117007236A patent/KR101318549B1/ko not_active Expired - Fee Related
- 2009-09-28 AR ARP090103715A patent/AR073692A1/es unknown
- 2009-09-28 TW TW098132749A patent/TWI393570B/zh not_active IP Right Cessation
- 2009-09-29 US US12/586,893 patent/US8003099B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 CO CO11024330A patent/CO6351795A2/es active IP Right Grant
- 2011-03-10 IL IL211684A patent/IL211684A0/en unknown
- 2011-03-16 ZA ZA2011/02004A patent/ZA201102004B/en unknown
- 2011-03-23 CR CR20110161A patent/CR20110161A/es not_active Application Discontinuation
- 2011-03-25 EC EC2011010911A patent/ECSP11010911A/es unknown
- 2011-03-28 CL CL2011000672A patent/CL2011000672A1/es unknown
- 2011-04-21 MA MA33789A patent/MA32725B1/fr unknown
- 2011-07-19 US US13/186,109 patent/US20130195844A1/en not_active Abandoned
-
2014
- 2014-02-27 JP JP2014036699A patent/JP2014128279A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110345A1 (es) | Anticuerpos contra la il17 humana | |
| PE20141188A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| PE20121542A1 (es) | Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20140814A1 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| PH12018501548A1 (en) | Bispecific t cell engaging antibody constructs | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| AR085383A1 (es) | Anticuerpos contra el il33r humano y usos de los mismos | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20110561A1 (es) | Anticuerpos contra il-6 | |
| PE20130206A1 (es) | Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| PE20141722A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| EA201791127A1 (ru) | Антитела, содержащие модифицированные константные участки тяжелой цепи | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos | |
| PE20141434A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |